Breast Carcinoma In Situ
NCI Definition: Stage 0 includes: Tis, N0, M0. Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.) 
Breast carcinoma in situs most frequently harbor alterations in TP53, PIK3CA, ESR1, NF1, and MAP3K1 .
PIK3CA Mutation, TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and PIK3CA Codon 1047 Missense are the most common alterations in breast carcinoma in situ .
There is 1 clinical trial for breast carcinoma in situ, of which 1 is open and 0 are completed or closed. Of the trial that contains breast carcinoma in situ as an inclusion criterion, 1 is early phase 1 (1 open).
Atorvastatin and metformin are the most common interventions in breast carcinoma in situ clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.